GlaxoSmithKline (GSK) Earns Media Impact Rating of 0.18

News headlines about GlaxoSmithKline (NYSE:GSK) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GlaxoSmithKline earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news articles about the pharmaceutical company an impact score of 46.5446294788984 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Here are some of the news articles that may have impacted Accern’s rankings:

Shares of GlaxoSmithKline (NYSE GSK) traded up $0.20 on Friday, hitting $35.55. The stock had a trading volume of 4,333,600 shares, compared to its average volume of 3,601,639. The company has a quick ratio of 0.44, a current ratio of 0.64 and a debt-to-equity ratio of 2.96. The stock has a market cap of $86,720.00, a PE ratio of 12.53, a PEG ratio of 1.96 and a beta of 0.97. GlaxoSmithKline has a fifty-two week low of $34.52 and a fifty-two week high of $44.53.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be paid a dividend of $0.5037 per share. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $2.01 annualized dividend and a yield of 5.67%. GlaxoSmithKline’s payout ratio is presently 156.69%.

Several equities analysts have weighed in on GSK shares. UBS raised GlaxoSmithKline from a “neutral” rating to a “buy” rating and lifted their target price for the company from $35.04 to $35.85 in a research report on Monday, November 27th. Zacks Investment Research downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Morgan Stanley downgraded GlaxoSmithKline from an “equal weight” rating to an “underweight” rating in a research report on Friday, September 8th. BidaskClub raised GlaxoSmithKline from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Finally, Argus reaffirmed a “buy” rating and issued a $50.00 target price on shares of GlaxoSmithKline in a research report on Thursday, August 31st. Three analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $39.37.

In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.00% of the stock is owned by insiders.

WARNING: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit